3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 1
3
Phase 1/2
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
264
Carcinoma, Non-Small-Cell Lung
219
Neoplasms
218
Leukemia, Myeloid, Acute
193
Multiple Myeloma
178
Colorectal Neoplasms
175
Melanoma
165
Prostatic Neoplasms
163
Lymphoma
145
Leukemia
142
Lymphoma, Non-Hodgkin
133
Glioblastoma
131
Pancreatic Neoplasms
127
Neoplasm Metastasis
118
Lung Neoplasms
118
Leukemia, Lymphocytic, Chronic, B-Cell
118
Ovarian Neoplasms
112
Precursor Cell Lymphoblastic Leukemia-Lymphoma
106
Recurrence
97
Myelodysplastic Syndromes
93
Hodgkin Disease
92
Lymphoma, Large B-Cell, Diffuse
89
Lymphoma, Follicular
89
Lymphoma, Mantle-Cell
83
Head and Neck Neoplasms
79
Carcinoma, Renal Cell
79
Brain Neoplasms
77
Sarcoma
73
Carcinoma, Hepatocellular
73
Squamous Cell Carcinoma of Head and Neck
71
Interventions
derazantinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Completed
×
Acrocephalosyndactylia
×
Clear all
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts